Renfuyiyao (600079.SH): The application for market approval for Dimethanesulfonate Lyriopyropamine capsules has been accepted.

Zhitong Finance and Economics APP News, Renfu Pharmaceutical (600079.SH) announced that the company's controlling subsidiary Yichang Renfu Pharmaceutical Co., Ltd. (hereinafter referred to as "Yichang Renfu", the company holds 80% of its equity) recently received the National Medical Products Administration approved and issued the drug registration and listing application for the drug Triamterene Methanesulfonate Capsules. Acceptance Notice.